Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANKU-Lung03: BL-B01D1 versus topotecan in relapsed small cell lung cancer after platinum chemotherapy and PD-1/PD-L1 therapy failure
CTR20241644Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in small cell lung cancer (SCLC), sponsored by Biokin Pharmaceutical. Started Aug 2024; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20241644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241644.